Alnylam Pharmaceuticals (ALNY) Revenue (2009 - 2026)

Alnylam Pharmaceuticals has reported Revenue for 18 years, with the latest figure at $1.2 billion in Q1 2026.

• For the quarter ending Q1 2026, Revenue rose 3790.58% year-over-year to $1.2 billion; the trailing twelve-month figure through Mar 2026 stood at $4.3 billion (up 140.31% YoY), and the FY2025 full-year result was $3.7 billion, up 65.19% from the prior year.
• Revenue for Q1 2026 stood at $1.2 billion, up from $1.1 billion in the prior quarter.
• The five-year high for Revenue was $1.2 billion in Q3 2025, with the low at $30.0 million in Q1 2025.
• Historically, Revenue has averaged $554.8 million across 5 years, with a median of $494.3 million in 2024.
• Annual changes were most pronounced in 2025 — Revenue plunged 93.93% — and 2026, when it surged 3790.58%.
• Alnylam Pharmaceuticals' Revenue stood at $335.0 million in 2022, then soared by 31.25% to $439.7 million in 2023, then jumped by 34.9% to $593.2 million in 2024, then surged by 84.95% to $1.1 billion in 2025, then rose by 6.39% to $1.2 billion in 2026.
• The last three Revenue figures came in at $1.2 billion (Q1 2026), $1.1 billion (Q4 2025), and $1.2 billion (Q3 2025), per Business Quant data.